Matches in Nanopublications for { ?s ?p "[Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion description "[Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP748930.RALO3lmE1T1lbCP9zp7zpoy7KV-Z6Cy-MkNdeU383YAI0130_assertion description "[Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP748930.RALO3lmE1T1lbCP9zp7zpoy7KV-Z6Cy-MkNdeU383YAI0130_provenance.